Follow
Marc Nazare
Marc Nazare
Group leader, Leibniz-Forschungsinstitut für Molekulare (FMP)
Verified email at fmp-berlin.de - Homepage
Title
Cited by
Cited by
Year
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
DA Ruess, GJ Heynen, KJ Ciecielski, J Ai, A Berninger, D Kabacaoglu, ...
Nature medicine 24 (7), 954-960, 2018
3422018
Evidence for C Cl/C Br⋅⋅⋅ π Interactions as an Important Contribution to Protein–Ligand Binding Affinity
H Matter, M Nazaré, S Güssregen, DW Will, H Schreuder, A Bauer, ...
Angewandte Chemie International Edition 48 (16), 2911-2916, 2009
2942009
A flexible, palladium-catalyzed indole and azaindole synthesis by direct annulation of chloroanilines and chloroaminopyridines with ketones
M Nazare, C Schneider, A Lindenschmidt, DW Will
Angewandte Chemie International Edition 43 (34), 4526-4528, 2004
1322004
Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray …
M Nazaré, DW Will, H Matter, H Schreuder, K Ritter, M Urmann, M Essrich, ...
Journal of medicinal chemistry 48 (14), 4511-4525, 2005
1212005
A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels
M Schewe, H Sun, Ü Mert, A Mackenzie, ACW Pike, F Schulz, ...
Science 363 (6429), 875-880, 2019
1152019
A General and Mild Palladium‐Catalyzed Domino Reaction for the Synthesis of 2H‐Indazoles
N Halland, M Nazaré, O R'kyek, J Alonso, M Urmann, A Lindenschmidt
Angewandte Chemie International Edition 48 (37), 6879-6882, 2009
1152009
Pyrazole-derivatives as factor Xa inhibitors
M Nazare, V Wehner, DW Will, H Matter
US Patent 7,910,606, 2011
812011
Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions
H Matter, DW Will, M Nazaré, H Schreuder, V Laux, V Wehner
Journal of medicinal chemistry 48 (9), 3290-3312, 2005
812005
Oxybenzamide derivatives useful for inhibiting factor Xa or viia
M Nazaré, DW Will, A Peyman, H Matter, G Zoller, U Gerlach
US Patent 6,953,857, 2005
662005
Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein–ligand complexes
M Nazaré, H Matter, DW Will, M Wagner, M Urmann, J Czech, ...
Angewandte Chemie International Edition 51 (4), 905-911, 2012
642012
An activatable lanthanide luminescent probe for time‐gated detection of nitroreductase in live bacteria
B Brennecke, Q Wang, Q Zhang, HY Hu, M Nazaré
Angewandte Chemie International Edition 59 (22), 8512-8516, 2020
632020
A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves' orbitopathy
P Marcinkowski, I Hoyer, E Specker, J Furkert, C Rutz, ...
Thyroid 29 (1), 111-123, 2019
622019
DOTAM derivatives as active cartilage-targeting drug carriers for the treatment of osteoarthritis
HY Hu, NH Lim, D Ding-Pfennigdorff, J Saas, KU Wendt, O Ritzeler, ...
Bioconjugate Chemistry 26 (3), 383-388, 2015
602015
A general and mild domino approach to substituted 1-aminoindoles
N Halland, M Nazaré, J Alonso, O R'kyek, A Lindenschmidt
Chemical communications 47 (3), 1042-1044, 2011
522011
Enantiospecific Synthesis of the (9S, 18R)‐Diastereomer of the Leukocyte Adhesion Inhibitor Cyclamenol A
M Nazaré, H Waldmann
Chemistry–A European Journal 7 (15), 3363-3376, 2001
502001
Synthesis of the (9S,18R) Diastereomer of Cyclamenol A
M Nazaré, H Waldmann
Angewandte Chemie International Edition 39 (6), 1125-1128, 2000
482000
Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors
N Halland, F Schmidt, T Weiss, J Saas, Z Li, J Czech, M Dreyer, ...
ACS medicinal chemistry letters 6 (1), 73-78, 2015
472015
N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel …
C Boldron, A Besse, MF Bordes, S Tissandié, X Yvon, B Gau, A Badorc, ...
Journal of medicinal chemistry 57 (17), 7293-7316, 2014
472014
Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla
M Nazare, DW Will, A Peyman, H Matter, G Zoller, U Gerlach
US Patent 7,067,665, 2006
462006
Identification and characterization of a single high‐affinity fatty acid binding site in human serum albumin
L Wenskowsky, H Schreuder, V Derdau, H Matter, J Volkmar, M Nazaré, ...
Angewandte Chemie 130 (4), 1056-1060, 2018
412018
The system can't perform the operation now. Try again later.
Articles 1–20